PROTHENA CORPORATION PUBLIC LIMITED COMPANY Share-based Compensation Arrangements by Share-based Payment Award, Options, Expirations in Period, Weighted Average Exercise Price
PROTHENA CORPORATION PUBLIC LIMITED COMPANY (PRTA) reported Share-based Compensation Arrangements by Share-based Payment Award, Options, Expirations in Period, Weighted Average Exercise Price of $25.91 per share for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-06.
Financial Statements › Notes › Share-Based Payment Arrangement, Disclosure › Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Forfeitures and Expirations in Period, Weighted Average Exercise Price
us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice · last filed 2026-08-06
- PROTHENA CORPORATION PUBLIC LIMITED COMPANY share-based compensation arrangements by share-based payment award, options, expirations in period, weighted average exercise price for the quarter ending 2026-03-31 was $24.93, a 3.82% decline year-over-year.
- PROTHENA CORPORATION PUBLIC LIMITED COMPANY share-based compensation arrangements by share-based payment award, options, expirations in period, weighted average exercise price for the quarter ending 2025-03-31 was $25.92, a 9.05% decline year-over-year.
- PROTHENA CORPORATION PUBLIC LIMITED COMPANY share-based compensation arrangements by share-based payment award, options, expirations in period, weighted average exercise price for the quarter ending 2024-03-31 was $28.50.
- PROTHENA CORPORATION PUBLIC LIMITED COMPANY share-based compensation arrangements by share-based payment award, options, expirations in period, weighted average exercise price for the quarter ending 2023-03-31 was $0.00.
- PROTHENA CORPORATION PUBLIC LIMITED COMPANY share-based compensation arrangements by share-based payment award, options, expirations in period, weighted average exercise price for fiscal 2025 was $39.64, a 25.05% increase from fiscal 2024.
- PROTHENA CORPORATION PUBLIC LIMITED COMPANY share-based compensation arrangements by share-based payment award, options, expirations in period, weighted average exercise price for fiscal 2024 was $31.70, a 55.19% decline from fiscal 2023.
- PROTHENA CORPORATION PUBLIC LIMITED COMPANY share-based compensation arrangements by share-based payment award, options, expirations in period, weighted average exercise price for fiscal 2023 was $70.74.
- PROTHENA CORPORATION PUBLIC LIMITED COMPANY share-based compensation arrangements by share-based payment award, options, expirations in period, weighted average exercise price for fiscal 2022 was $0.00, a 100.00% decline from fiscal 2021.
| Period end | Share-based Compensation Arrangements by Share-based Payment Award, Options, Expirations in Period, Weighted Average Exercise Price 3 month | Share-based Compensation Arrangements by Share-based Payment Award, Options, Expirations in Period, Weighted Average Exercise Price 6 month | Share-based Compensation Arrangements by Share-based Payment Award, Options, Expirations in Period, Weighted Average Exercise Price 9 month | Share-based Compensation Arrangements by Share-based Payment Award, Options, Expirations in Period, Weighted Average Exercise Price 12 month |
|---|---|---|---|---|
| 2026-06-30 | $25.91 10-Q · filed 2026-08-06 | |||
| 2026-03-31 | $24.93 10-Q · filed 2026-05-07 | |||
| 2025-12-31 | $39.64 10-K · filed 2026-02-27 | |||
| 2025-09-30 | $27.70 10-Q · filed 2025-11-06 | |||
| 2025-06-30 | $25.64 10-Q · filed 2025-08-04 | |||
| 2025-03-31 | $25.92 10-Q · filed 2025-05-08 | |||
| 2024-12-31 | $31.70 10-K · filed 2025-02-27 | |||
| 2024-09-30 | $30.92 10-Q · filed 2024-11-12 | |||
| 2024-06-30 | $27.96 10-Q · filed 2024-08-08 | |||
| 2024-03-31 | $28.50 10-Q · filed 2024-05-08 | |||
| 2023-12-31 | $70.74 10-K · filed 2024-02-22 | |||
| 2023-09-30 | $0.00 10-Q · filed 2023-11-02 | |||
| 2023-06-30 | $0.00 10-Q · filed 2023-08-03 | |||
| 2023-03-31 | $0.00 10-Q · filed 2023-05-04 | |||
| 2022-12-31 | $0.00 10-K · filed 2023-02-28 | |||
| 2022-09-30 | $0.00 10-Q · filed 2022-11-03 | |||
| 2022-06-30 | $0.00 10-Q · filed 2022-08-08 | |||
| 2022-03-31 | $0.00 10-Q · filed 2022-05-05 | |||
| 2021-12-31 | $40.98 10-K · filed 2022-02-25 | |||
| 2021-09-30 | $40.98 10-Q · filed 2021-11-04 | |||
| 2021-06-30 | $40.98 10-Q · filed 2021-08-05 | |||
| 2021-03-31 | $40.98 10-Q · filed 2021-05-11 | |||
| 2020-12-31 | $30.13 10-K · filed 2021-02-26 | |||
| 2020-09-30 | $33.61 10-Q · filed 2020-11-04 | |||
| 2020-06-30 | $33.61 10-Q · filed 2020-08-06 | |||
| 2020-03-31 | $34.36 10-Q · filed 2020-05-06 | |||
| 2019-12-31 | $43.50 10-K · filed 2020-03-03 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| DiaMedica Therapeutics Inc. (DMAC) | United States | $0.423B | -10.11 |
| CYPHERPUNK TECHNOLOGIES INC. (CYPH) | United States | $0.438B | -75.63 |
| Atea Pharmaceuticals, Inc. (AVIR) | United States | $0.414B | -2.26 |
| ARS Pharmaceuticals, Inc. (SPRY) | United States | $0.414B | -3.70 |
| Quoin Pharmaceuticals Ltd. (QNRX) | $0.443B | -17.85 | |
| RELMADA THERAPEUTICS, INC. (RLMD) | United States | $0.406B | -11.92 |
| Opus Genetics, Inc. (IRD) | United States | $0.406B | -3.16 |
| Arcturus Therapeutics Holdings Inc. (ARCT) | $0.402B | -2.05 | |
| GALECTIN THERAPEUTICS INC (GALT) | United States | $0.399B | -11.06 |
| MapLight Therapeutics, Inc. (MPLT) | United States | $0.459B | -7.10 |